To the editor,Pancreatic ductal adenocarcinoma(PDAC)has the worst prognosis among all common malignant solid tumors,with a 5-year overall survival(OS)rate of less than 10%[1].Few effective targets for anticancer ther-...To the editor,Pancreatic ductal adenocarcinoma(PDAC)has the worst prognosis among all common malignant solid tumors,with a 5-year overall survival(OS)rate of less than 10%[1].Few effective targets for anticancer ther-apy have been confirmed in pancreatic cancer.Recently,it was substantiated that pancreatic cancer patients carry-ing deleterious mutations of the DNA damage response(DDR)genes are more likely to benefit from platinum-based chemotherapy[2]and poly(adenosine diphosphate-ribose)polymerase(PARP)inhibitor[3].展开更多
基金supported by a senior investigator LWW’s fundings from the Innovation Group Project of Shanghai Municipal Health Commission(2019CXJQ03),National Natural Science Foundation of China(81874048),Shang-haiMunicipal Commission of Health and Family Planning(2018ZHYL0223),Fostering Fund of Renji Hospital affili-ated to Shanghai Jiao Tong University School of Medicine(PYIV-17-001),Shanghai Municipal Commission of Health and Family Planning Grant(2018ZHYL0223),Clinical Research Plan of SHDC(No.SHDC2020CR1035B),Shang-hai Key Clinical Speciality(Oncology),Shanghai leading talents project,Innovative research teamof high-level local universities in Shanghai.Also supported by XFZ’s grant from Clinical plus Excellence Project(2020ZYA003)from Shanghai Nucleic Acid Chemistry and Nanomedicine Key Laboratory.
文摘To the editor,Pancreatic ductal adenocarcinoma(PDAC)has the worst prognosis among all common malignant solid tumors,with a 5-year overall survival(OS)rate of less than 10%[1].Few effective targets for anticancer ther-apy have been confirmed in pancreatic cancer.Recently,it was substantiated that pancreatic cancer patients carry-ing deleterious mutations of the DNA damage response(DDR)genes are more likely to benefit from platinum-based chemotherapy[2]and poly(adenosine diphosphate-ribose)polymerase(PARP)inhibitor[3].
